UID:
almahu_9949943820902882
Umfang:
1 online resource (xxiii, 439 pages) :
,
illustrations (some colour)
ISBN:
0-443-14045-6
,
9780443140457
,
0443140456
Anmerkung:
Front Cover -- Advanced Drug Delivery Systems for Colonic Disorders -- Copyright Page -- Contents -- List of contributors -- 1 Introduction to colonic disorders -- 1.1 Introduction -- 1.1.1 Anatomy -- 1.1.2 Transport time -- 1.1.3 Circulatory network -- 1.1.4 Microvilli -- 1.1.5 Intestinal fluid -- 1.1.6 Microbial environment -- 1.2 Classification of colon disorders -- 1.3 Inflammatory bowel disease -- 1.3.1 Crohn's disease -- 1.3.2 Ulcerative colitis -- 1.4 Diverticulosis -- 1.5 Colon cancer -- 1.6 Formulation approaches for targeting colon -- 1.6.1 pH-dependent drug delivery systems -- 1.6.2 Polymer-based nano-/microparticles -- 1.6.3 Lipid-based formulations -- 1.6.4 Tablets and capsules -- 1.6.5 Enzyme-sensitive drug delivery systems -- 1.6.5.1 Polysaccharide-based systems -- 1.6.5.2 Phloral technology -- 1.6.6 Ligand/receptor-mediated drug delivery system -- 1.6.6.1 Antibodies -- 1.6.6.2 Folic acid -- 1.6.7 Magnetically driven drug delivery system -- 1.6.8 Rectal drug delivery -- 1.7 Conclusion -- References -- 2 Cellular and molecular mechanisms involved in colonic disorders -- 2.1 Introduction -- 2.2 Molecular mechanisms involved in colonic disorders -- 2.2.1 Role of inflammatory cytokines in colonic disorders -- 2.2.2 Altered neurotransmitter signaling in colonic disorders -- 2.2.3 Role of eicosanoids -- 2.2.4 Role of nitric oxide -- 2.2.5 Oxidative stress in colonic disorders -- 2.2.6 Role of bidirectional neural-gut connection in Colonic disorders -- 2.2.7 Apoptosis in Colonic disorders -- 2.2.8 Role of neuroendocrine peptides in colonic disorders -- 2.2.9 Genetic mutations in colonic disorders -- 2.3 Conclusion -- References -- 3 Current approaches for treatment of colonic disorder -- 3.1 Introduction -- 3.2 Different type of colonic disorder and their treatment -- 3.2.1 Diverticular disease.
,
3.2.1.1 Medical treatment of diverticular disease -- 3.2.1.1.1 5-ASA in diverticular disease -- 3.2.1.1.2 Probiotics in diverticular disease -- 3.2.1.1.3 Surgery -- 3.2.2 Inflammatory bowel disease -- 3.2.2.1 Current therapeutic -- 3.2.2.2 Antibiotics, prebiotics, and probiotics -- 3.2.2.3 Biologics -- 3.3 Alternative and complementary approaches -- 3.4 Neurokinin antagonists and & -- Kappa -- -opioid agonists -- 3.4.1 Colorectal cancer -- 3.4.1.1 Medication and hormones regular -- 3.4.1.2 Preventive strategies -- 3.4.1.3 Primary prevention -- 3.4.1.4 Secondary prevention -- 3.4.1.5 Treatment strategies -- 3.4.1.6 Targeted therapy -- 3.4.1.7 Gene therapy -- 3.4.1.8 Immunotherapy -- 3.4.1.9 Monoclonal antibody therapy -- 3.4.1.10 Cancer vaccines -- 3.4.1.11 OncoVAX -- 3.4.1.12 Adoptive T-cell therapy -- 3.5 Ischemic colitis -- 3.6 Constipation -- 3.6.1 Osmotic laxatives -- 3.6.2 Prokinetic agents -- 3.6.3 Probiotics -- 3.7 Conclusion and future perspective -- References -- 4 Polysaccharides based drug delivery systems for the treatment of colon diseases -- 4.1 Introduction -- 4.2 Types of polysaccharides -- 4.2.1 Chitosan -- 4.2.2 Alginate -- 4.2.3 Pectin -- 4.2.4 Guar gum -- 4.2.5 Dextran -- 4.2.6 Starch -- 4.2.7 Locust bean gum -- 4.2.8 Hyaluronic acid -- 4.2.9 Inulin -- 4.2.10 Cyclodextrins -- 4.2.11 Arabinoxylans -- 4.2.12 Chondroitin sulfate -- 4.3 Tempering in structural arrangement of polysaccharides -- 4.3.1 Physical interaction -- 4.3.2 Chemical interaction -- 4.4 Physicochemical properties of polysaccharides -- 4.5 Biotolerance properties -- 4.6 Development of theranostics -- 4.7 Polysaccharide-based devivery systems -- 4.7.1 Polysaccharide containing microbeads -- 4.7.2 Microspheres made of polysaccharide -- 4.7.3 Nanoparticles derived from polysaccharides -- 4.7.4 Nano-sized spheres of polysaccharide.
,
4.7.5 A nano gel based on polysaccharides -- 4.7.6 Polysaccharide-based quantum dots -- 4.7.7 Polysaccharide derived liposomes -- 4.7.8 Microcapsules developed from polysaccharides -- 4.8 Analyses of colon-specific carriers in vitro and in vivo -- 4.8.1 In vitro evaluation -- 4.8.2 In vivo evaluation -- 4.9 Conclusion -- References -- 5 Synthetic polymers as biomaterials for the treatment of colon diseases -- 5.1 Introduction -- 5.2 Colon diseases -- 5.2.1 Inflammatory bowel diseases -- 5.2.1.1 Colorectal cancer -- 5.3 Colon delivery: physiology and biopharmaceutical considerations -- 5.4 Synthetic polymers as biomaterials for colon drug delivery system -- 5.4.1 pH-dependent polymers -- 5.4.2 Erodible or swellable or time-dependent polymers -- 5.4.2.1 Hydroxypropyl methylcellulose -- 5.4.2.2 Hydroxypropyl cellulose and hydroxyethyl cellulose -- 5.4.3 Water-insoluble polymers (ethyl cellulose) -- 5.4.4 Bacterially triggered polymers (pectin, chitosan, cyclodextrin) -- 5.4.4.1 Polysaccharide modification -- 5.4.4.1.1 Guar gum -- 5.4.4.1.2 Pectin -- 5.4.4.1.3 Chitosan -- 5.4.4.1.4 Dextran -- 5.4.5 Bioresorbable polymers -- 5.5 Industrial patents and marketed preparations -- 5.6 Conclusion -- References -- 6 Mucoadhesive polymers as biomaterials for the treatment of colon disorders -- 6.1 Introduction -- 6.1.1 Mucoadhesion -- 6.1.1.1 Theories of mucoadhesion -- 6.1.1.1.1 Wetting theory -- 6.1.1.1.2 Adsorption theory -- 6.1.1.1.3 Diffusion theory -- 6.1.1.1.4 Fracture theory -- 6.1.1.1.5 Electronic theory -- 6.1.2 Mechanism of mucoadhesion -- 6.1.3 Factors affecting the mechanism of mucoadhesion -- 6.2 Mucoadhesive drug delivery systems -- 6.2.1 Characteristics of ideal mucoadhesive polymer -- 6.2.2 Classification of the mucoadhesive polymers -- 6.3 Mucoadhesive polymers in drug delivery system.
,
6.3.1 Mucoadhesive polymers in the treatment of colon disorders -- 6.3.1.1 Hydrophilic polymers -- 6.3.1.2 Hydrogels -- 6.3.1.3 Thiolated polymers -- 6.3.1.4 Lectin-based polymers -- 6.3.2 Delivery sites of mucoadhesive polymers -- 6.3.2.1 Buccal cavity -- 6.3.2.2 Vaginal and rectal lumen -- 6.3.2.3 Gastrointestinal tract -- 6.3.3 Commercial mucoadhesive drug delivery system -- 6.3.4 Advantages of mucoadhesive-based drug delivery system in the treatment of colon disorders -- 6.4 Recent advances in mucoadhesive polymers for colon disorders -- 6.4.1 Mucoadhesive microspheres -- 6.4.2 Mucoadhesive nanoparticles -- 6.4.3 Dual-drug-loaded mucoadhesive nanoparticles -- 6.4.4 Mucoadhesive chitosan-based nanoparticles -- 6.4.5 Naturally occurring biopolymers -- 6.4.5.1 Amino acid/protein-based mucoadhesive polymers -- 6.4.5.2 Snail-produced mucin proteins -- 6.4.5.3 Zwiterrionic polymeric nanoparticles as mucoadhesive agents -- 6.5 Limitations of mucoadhesive polymers-based drug delivery approaches for the treatment of colon disorders -- 6.6 Future perspectives -- 6.7 Conclusion -- References -- 7 Colon-responsive oral drug delivery for combating colonic disorders -- 7.1 Introduction -- 7.2 Fundamentals of encapsulation technologies for oral delivery for colon diseases -- 7.3 Recent literature in colon-responsive drug delivery -- 7.3.1 pH-sensitive colon-responsive drug delivery -- 7.3.2 Prodrug -- 7.3.3 Time-dependent colon-responsive drug delivery -- 7.3.4 Nanotools for colon-responsive drug delivery -- 7.3.5 Other approaches for colon-responsive drug delivery -- 7.4 Conclusion -- References -- 8 Colon-responsive targeted drug delivery for treating colonic disorder -- 8.1 Introduction -- 8.2 Physiology of the gastrointestinal tract -- 8.3 Physicochemical properties of drugs influencing CDDS.
,
8.4 Different approaches to colon-targeted drug delivery systems -- 8.4.1 Multistimuli systems for colonic drug delivery via the oral route -- 8.4.2 Superporous hydrogels as CDDS -- 8.4.3 pH-Dependent drug delivery systems -- 8.4.4 Lipid-based formulations -- 8.4.5 Bacterial enzymes-based drug delivery system -- 8.4.6 Polysaccharide-based systems -- 8.4.6.1 Polymeric micelles -- 8.4.7 Liposomes in colon-targeted drug delivery systems -- 8.4.8 Microspheres for controlled release of drug molecules -- 8.4.9 Magnetic nanoparticles for colon-targeted drug delivery systems -- 8.5 Challenges and conclusion -- References -- 9 Advancement in targeted drug delivery systems in managing colonic disorders -- 9.1 Introduction -- 9.2 Colon-responsive targeted drug delivery approaches -- 9.2.1 Prodrug -- 9.2.2 pH-sensitive system -- 9.2.3 Bacterial-enzyme activated -- 9.2.3.1 Osmotically controlled -- 9.2.4 Coated tablets and capsules-based approaches -- 9.2.5 Nanotechnology-based targeting -- 9.2.6 Theranostic approach -- 9.2.7 Bioelectronic devices for colon targeting -- 9.2.8 Computer-assisted formulation design development for targeting colon -- 9.3 Conclusion -- References -- 10 Nutraceuticals and phytoceuticals in the treatment of colon disorders -- 10.1 Introduction -- 10.2 Nutraceuticals as drug delivery systems for colonic disorders -- 10.2.1 Functional colonic disorders -- 10.2.2 Constipation -- 10.2.3 Irritable bowel syndrome -- 10.2.4 Functional dyspepsia -- 10.2.5 Gastroesophaegeal reflux disease -- 10.2.6 Various structural colonic disorders -- 10.2.7 Inflammatory bowel disease -- 10.2.8 Gastrointestinal cancer -- 10.2.9 Diverticular disease -- 10.2.10 Colorectal cancer -- 10.3 Plant materials as DDS for colonic disorders -- 10.3.1 Curcumin -- 10.3.2 Phenolic compounds -- 10.3.3 Halocynthiaxanthin -- 10.3.4 Glycyrrhizin glycyrrhizin -- 10.3.5 Saponins.
,
10.3.6 Probiotics, prebiotics, and synbiotics.
Weitere Ausg.:
ISBN 9780443140440
Sprache:
Englisch
Bookmarklink
